Correction to: Leukemia (2014) 28, 2155–2164; doi:10.1038/leu.2014.119; published online 25 April 2014
Following the publication of this article, the authors noted that the loading control (β-actin) for the primary AML cells data presented in Figure 7b was incorrect. The correct western blot for the loading control (β-actin) has been added to Figure 7b. This correction neither changes the interpretation of the data nor does it alter the overall conclusions of the study. The corrected Figure 7b appears below:
Treatment with SP2509 and/or PS significantly enhances PS-mediated loss of viability of CD34+ primary AML cells and improves the survival of mice bearing AML xenografts and primagrafts. (b) Primary AML cells were treated with SP2509 and/or PS as indicated for 24 hours. Total cell lysates were prepared and immunoblot analyses were conducted for the expression levels of c-Myc, p21, p27, BIM, and β-actin in the lysates.
Additional information
The online version of the original article can be found at 10.1038/leu.2014.119
Rights and permissions
About this article
Cite this article
Fiskus, W., Sharma, S., Shah, B. et al. Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 31, 1658 (2017). https://doi.org/10.1038/leu.2017.77
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.77
This article is cited by
-
Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells
Cell Death Discovery (2024)
-
c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance
Cell Death & Disease (2022)
-
Molecular targeting in acute myeloid leukemia
Journal of Translational Medicine (2017)
